DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SILODOSIN

« Back to Dashboard

Clinical Trials for Silodosin

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00224107	A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo	Completed	Watson Pharmaceuticals	Phase 3	A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
NCT00224120	A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo	Completed	Watson Pharmaceuticals	Phase 3	A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.
NCT00224133	The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months	Completed	Watson Pharmaceuticals	Phase 3	A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.
NCT00359905	Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH	Completed	Recordati Industria Chimica e Farmaceutica S.p.A.	Phase 3	A new drug for the treatment of benign prostatic hyperplasia is compared with placebo and tamsulosin (a drug belonging to the same therapeutic class) for to determine if it is safe and effective (the first phase of the study lasts approximately 18 weeks) and then is used for another 9 months to determine its long-term safety.
NCT00740779	Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.	Completed	Watson Pharmaceuticals	Phase 2	The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week treatment period. The secondary objective is to compare the safety of silodosin 4 and 8 mg once daily with placebo.
NCT00793819	A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia	Completed	Watson Pharmaceuticals	Phase 2	Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH

Clinical Trial Conditions for Silodosin

Condition Name

Condition Name for Silodosin
Intervention	Trials
Benign Prostatic Hyperplasia	6
Nocturia	2
Ureteral Stone	2
Kidney Stones	2

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Silodosin
Intervention	Trials
Prostatic Hyperplasia	10
Hyperplasia	9
Ureterolithiasis	3
Ureteral Calculi	3

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Silodosin

Trials by Country

Trials by Country for Silodosin
Location	Trials
United States	130
Korea, Republic of	9
Japan	2
Canada	1
France	1

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Silodosin
Location	Trials
Pennsylvania	7
New York	6
California	6
Florida	5
Alabama	5

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Silodosin

Clinical Trial Phase

Clinical Trial Phase for Silodosin
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	6
Phase 2	6

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Silodosin
Clinical Trial Phase	Trials
Completed	14
Recruiting	2
Terminated	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Silodosin

Sponsor Name

Sponsor Name for Silodosin
Sponsor	Trials
Watson Pharmaceuticals	6
JW Pharmaceutical	5
Recordati Industria Chimica e Farmaceutica S.p.A.	2

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Silodosin
Sponsor	Trials
Industry	15
Other	15

Export unavailable in trial.
Subscribe for complete access.